CPG
ACRS icon

Cornerstone Planning Group’s Aclaris Therapeutics ACRS Stock Holding History

Cornerstone Planning Group’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-580
Closed -$789 – 1262
2024
Q1 		$789 Buy
+580
New +$692 ﹤0.01% 831

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Cornerstone Planning Group's ACRS Position: Q2 2024 in Review

Cornerstone Planning Group sold out of Aclaris Therapeutics (ACRS) in Q2 2024, closing a stake of 580 shares — an estimated $789 sold.

Cornerstone Planning Group first reported a position in ACRS in Q1 2024 and held it in 1 quarter. The position peaked at $789 in Q1 2024. 98 funds tracked by Wall St. Rank hold ACRS as of Q2 2024.

  • Cornerstone Planning Group reported no remaining Aclaris Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Cornerstone Planning Group sold 580 Aclaris Therapeutics shares in Q2 2024, an estimated $789.
  • Cornerstone Planning Group first reported a position in Aclaris Therapeutics in Q1 2024 and held it in 1 quarter.
  • Cornerstone Planning Group's Aclaris Therapeutics position peaked at $789 in Q1 2024.
  • 98 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2024.

Based on Cornerstone Planning Group's 13F filing for Q2 2024, filed 13 Aug 2024.